title: Merck Initiates Three New Phase 2b Trials for Investigational Inflammatory Drug Tulisokibart
source: Yahoo
date: 2025-10-13
url: https://finnhub.io/api/news?id=6bac84ab156788b200dedd2b34d807ac3ab852118779e4b9296f7b5bea781d6c
Merck & Co. Inc. (NYSE:MRK) is one of the most promising stocks under $100. On October 6, Merck & Co. announced the initiation of three new Phase 2b trials for tulisokibart (MK-7240). Tulisokibart is an investigational humanized monoclonal antibody targeting tumor necrosis factor/TNF-like cytokine 1A/TL1A. The program expansion reflects Merck’s ongoing commitment to immune-mediated inflammatory […]
